{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:00:16Z","timestamp":1765976416189,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coph.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T05:14:37Z","timestamp":1604812477000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Design strategies for long-acting anti-HIV pharmaceuticals"],"prefix":"10.1016","volume":"54","author":[{"given":"Yali","family":"Sang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fener","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.005_bib0005","doi-asserted-by":"crossref","first-page":"102974","DOI":"10.1016\/j.bioorg.2019.102974","article-title":"Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains","volume":"89","author":"Sang","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.coph.2020.10.005_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12905-020-01011-8","article-title":"Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy","volume":"20","author":"Benning","year":"2020","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.coph.2020.10.005_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/COH.0000000000000165","article-title":"Current state and limitations of daily oral therapy for treatment","volume":"10","author":"Solomon","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111603","article-title":"Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"182","author":"Sang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coph.2020.10.005_bib0025","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1021\/acs.jmedchem.9b01446","article-title":"Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety, and oral pharmacokinetic profiles","volume":"62","author":"Sang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2020.10.005_bib0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.368.6493.807","article-title":"Long-acting drug acts like a short-term AIDS vaccine","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.10.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234666","article-title":"\u201cA dream come true\u201d: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania","volume":"15","author":"Kerrigan","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2020.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.005_sbref0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2020.10.005_sbref0050","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcv.2016.11.015","article-title":"Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting","volume":"87","author":"Marinaro","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coph.2020.10.005_bib0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14656566.2017.1316369","article-title":"Advances in therapy for the prevention of HIV transmission from mother to child","volume":"18","author":"Moretton","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coph.2020.10.005_bib0065","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/AAC.00267-13","article-title":"Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy","volume":"57","author":"Gautam","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2020.10.005_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","article-title":"New-generation high-potency and designer antibodies: role in HIV-1 treatment","volume":"69","author":"Gama","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coph.2020.10.005_sbref0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2020.10.005_sbref0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0090","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coph.2020.10.005_bib0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.005_bib0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cpt.1284","article-title":"Modern human immunodeficiency virus therapy: progress and prospects","volume":"105","author":"Flexner","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2020.10.005_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study","volume":"14","author":"Cohen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2020.10.005_bib0125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.005_sbref0130","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000470","article-title":"Antiretroviral implants for treatment and prevention of HIV infection","volume":"13","author":"Flexner","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.005_bib0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coph.2020.10.005_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coph.2020.10.005_sbref0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment","volume":"34","author":"DeJesus","year":"2018","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.coph.2020.10.005_bib0150","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.coph.2020.10.005_bib0155","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2020.10.005_sbref0160","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.coph.2020.10.005_bib0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coph.2020.10.005_bib0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1039\/C8TB01597J","article-title":"Tuning HIV drug release from a nanogel-based in situ forming implant by changing nanogel size","volume":"7","author":"Town","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.coph.2020.10.005_bib0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.005_bib0180","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1074\/jbc.M114.614305","article-title":"Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase","volume":"290","author":"Bernatchez","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2020.10.005_bib0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/ph12020062","article-title":"Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase","volume":"12","author":"Singh","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.coph.2020.10.005_bib0190","unstructured":"https:\/\/investors.merck.com\/news\/press-release-details\/2019\/Merck-Presents-Early-Evidence-on-Extended-Delivery-of-Investigational-Anti-HIV-1-Agent-Islatravir-MK-8591-via-Subdermal-Implant\/default.aspx. [Accessed 1 May 2020]."},{"key":"10.1016\/j.coph.2020.10.005_bib0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/COH.0000000000000591","article-title":"Long-acting implants to treat and prevent HIV infection","volume":"15","author":"Weld","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.005_sbref0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06490-w","article-title":"Ultra-long-acting removable drug delivery system for HIV treatment and prevention","volume":"9","author":"Kovarova","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2020.10.005_bib0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/pharmaceutics11080374","article-title":"Topical inserts: a versatile delivery form for HIV prevention","volume":"11","author":"Peet","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coph.2020.10.005_bib0210","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jconrel.2015.08.042","article-title":"Drug delivery strategies and systems for HIV\/AIDS pre-exposure prophylaxis and treatment","volume":"219","author":"Nelson","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.coph.2020.10.005_bib0215","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004174","article-title":"Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and\/or maraviroc in a randomized, placebo controlled trial","volume":"95","author":"Dezzutti","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coph.2020.10.005_bib0220","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.005_sbref0225","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/ciy654","article-title":"Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in us postmenopausal women","volume":"68","author":"Chen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2020.10.005_bib0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/COH.0000000000000598","article-title":"Topical delivery of long-acting antiretrovirals to prevent HIV acquisition","volume":"15","author":"Palanee-Phillips","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.005_bib0235","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7150\/thno.39847","article-title":"Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues","volume":"10","author":"Kevadiya","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.coph.2020.10.005_bib0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/v12040412","article-title":"The potential of long-acting, tissue-targeted synthetic nanotherapy for delivery of antiviral therapy against HIV infection","volume":"12","author":"Andersen","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.coph.2020.10.005_sbref0245","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41563-020-0731-7","article-title":"Long-acting antiretroviral therapy","volume":"19","author":"Soriano","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.coph.2020.10.005_bib0250","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.coph.2020.10.005_bib0255","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2020.05.022","article-title":"Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs","volume":"324","author":"Surve","year":"2020","journal-title":"J Control Release"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922030103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922030103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:54:18Z","timestamp":1761461658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148922030103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":51,"alternative-id":["S147148922030103X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.005","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design strategies for long-acting anti-HIV pharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}